First Trust Nasdaq Lux Digital Health Solutions ETF

Oscar Health CFO Richard Scott Blackley Sells 100k Shares for $2.32M

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Dexcom Announces Launch of Dexcom Flex Continuous Glucose Monitoring System in Germany

Manulife Singapore to Launch Shield™ Multi-Cancer Test with Guardant Health in May 2026

Barclay's Analyst Matt Miksic Maintains Sell Rating on Dexcom with $64 Target

Dexcom Investor Day: Focus on G8 New Product, Doubling US CGM Coverage, and International Expansion Strategy

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Dexcom Announces 2030 Targets: 10% Revenue Growth and $10B Buyback

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Illumina CEO joins China delegation, stock price rises

IQVIA Reports Strong Q1 Earnings and Raises Full-Year Guidance

ViCentra Launches Its New Kaleido Insulin Delivery Patch Pump System Commercially

Brummer Multi Strategy AB Upgrades IQVIA Holdings Inc. Shares

ASR Vermogensbeheer N.V. Significantly Reduces Holdings in IQVIA Holdings Inc.

Guardant Health Reports Significant Losses in Q4 2025 Earnings

Oscar Health's stock target price raised to $20.09

Citigroup analyst maintains buy rating on ResMed

QRG Capital Management Inc. Significantly Increased Holdings in Natera Inc.

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

DOCS

HEAL

Doximity, Inc. reported Q4 and full-year fiscal 2026 results with revenue growth but declining net income. The company faces challenges with softer fiscal 2027 guidance due to increased AI spending. A new integration with Aledade's platform aims to enhance its AI tools' role in clinical workflows. Analysts express caution over revenue growth and margin pressures, while Doximity's long-term projections suggest significant upside potential. Investors are advised to consider various perspectives before making decisions.

Simplywall

Doximity

iShares Expanded Tech Software Sector ETF

Global X HealthTech ETF

SPDR S&P Software

Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed

LGHT

Barclays has downgraded Doximity (NYSE:DOCS) from a 'strong-buy' to a 'hold' rating. Other analysts have also reduced their price targets, with Mizuho lowering it to $26, Goldman Sachs to $24, and BMO to $20. Doximity's stock currently has a consensus rating of 'Hold' and a target price of $30.62. The company has a market cap of $3.50 billion and recently approved a $500 million stock buyback program.

Market Beat

Langar Global HealthTech ETF

Barclays

Mizuho Financial

Mizuho Financial Group, Inc.

Goldman Sachs

Bank of Montreal

Atlantic Union Bankshares

GS Hldg R

ATLANTIC UNION BANKSHARES CORP 6.875% DEP SH RP 1/400 NON CU PR PF SR A

Atlantic Union Bankshares Corporation

Barclays Downgrades Doximity (NYSE:DOCS) to Hold

Doximity, Inc. (NYSE:DOCS) has received a consensus recommendation of 'Moderate Buy' from 24 analysts. Thirteen rated it as hold, nine as buy, and two as strong buy. The average 12-month target price is $30.62. Recent analyst reports show varied price targets, with BMO Capital Markets lowering theirs to $20 and Piper Sandler raising it to $42. Insider transactions revealed significant stock sales, and institutional investors hold 87.19% of shares.

Piper Sandler Cos

Morgan Stanley

Evercore

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Doximity, Inc. (NYSE:DOCS) Given Average Recommendation of "Moderate Buy" by Analysts

JPMorgan Chase & Co. has lowered its price target for Doximity (NYSE:DOCS) from $33.00 to $28.00, maintaining a "neutral" rating. This suggests a potential upside of 60.38% from the previous close. Other brokerages have also adjusted their targets, with Robert W. Baird setting a target of $18.00, BMO Capital Markets at $20.00, and Bank of America at $47.00. Doximity's stock traded down to $17.46, with a market cap of $3.22 billion. Insiders have sold shares recently, indicating potential concerns about the stock's valuation.

JPMorgan Chase

Defiance Daily Target 2X Long JPM ETF

JPMorgan Chase & Co. Lowers Doximity (NYSE:DOCS) Price Target to $28.00

Doximity (DOCS) shares dropped 24% following mixed Q4 results and a weaker FY2027 outlook, prompting analysts to downgrade ratings. Wells Fargo's Stan Berenshteyn lowered the rating to Hold and cut the price target to $18, citing risks in AI competition and rising costs. BTIG's David Larsen also downgraded the stock, highlighting a challenging macro environment and weak pharma demand. Despite the downturn, analysts maintain a Moderate Buy consensus on DOCS, with an average price target of $28.12, suggesting a potential upside of 56.91%.

Tip Ranks

Wells Fargo

Veeva Systems -CL

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Why Is Doximity Stock (DOCS) Falling Today, 5/14/26?

Doximity shares fell 24% following disappointing Q4 results, prompting analysts to downgrade ratings and lower price targets. KeyBanc Capital Markets downgraded the stock from Overweight to Sector Weight, citing weak fiscal 2027 growth guidance of 3%-5% and challenges in the pharma ad market. Needham maintained a Buy rating but reduced the price target from $55 to $27, noting revenue growth of 5.1% year-on-year but concerns over decelerating growth. Doximity's stock was trading at $17.70 at the time of the report.

Fidelity

Doximity Sinks 24% As AI Push Fails To Ease Growth Fears

Doximity (DOCS) fell approximately 25% to an all-time low following disappointing Q4 fiscal 2026 results, leading to a downgrade by KeyBanc Capital Markets. The company's guidance did not meet Wall Street expectations, marking the lowest stock price since its IPO in 2021.

KeyCorp

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

Doximity hits an all-time low after Q4 results; KeyBanc downgrades

Doximity (NYSE:DOCS) reached a new 52-week low of $17.32 following insider selling, with shares last trading at $17.8060. Insider Siddharth Sitaram sold 2,309 shares at $25.77, while Director Kira Scherer Wampler sold 9,000 shares at $26.06. Analysts have mixed views, with price targets ranging from $18.00 to $34.00. Despite reporting a 5.1% revenue increase, the company missed earnings expectations and provided lower revenue guidance for FY2027, raising concerns about growth. Doximity's board approved a $500 million stock repurchase program, indicating confidence in the stock's value.

Doximity (NYSE:DOCS) Sets New 52-Week Low After Insider Selling

Doximity, Inc.'s average stock price target has been reduced from $36.74 to $31.11, indicating a potential upside of approximately 33% based on the May 13 closing price. The forecasts from 22 analysts range from $17 to $55 per share. The consensus rating remains a 'Buy' from 25 analysts, with 13 Buys, 12 Holds, and no Sells. This information is sourced from FactSet and does not constitute investment advice.

TradingView

Factset Research

Doximity, Inc. Stock 12‑Month Price Target Cut to $28.11, Implies 20% Upside

Doximity's shares fell 24% after the company reported weaker-than-expected quarterly profits and issued disappointing fiscal 2027 revenue guidance, raising concerns about slowing growth and increased AI spending. The stock is down over 45% this year as analysts cut price targets, with Needham lowering its target to $27 and Evercore ISI to $19. Doximity's adjusted earnings were 26 cents per share, below expectations, while revenue rose 5% to $145.4 million. The company forecasts first-quarter revenue below Wall Street estimates, indicating potential challenges in monetizing AI investments amid rising competition.

Invezz

Doximity plunges 24% on weak guidance, analysts slash PTs on increased AI spending

First Trust Nasdaq Lux Digital Health Solutions ETF(EKG.US)

Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed

Barclays Downgrades Doximity (NYSE:DOCS) to Hold

Doximity, Inc. (NYSE:DOCS) Given Average Recommendation of "Moderate Buy" by Analysts

JPMorgan Chase & Co. Lowers Doximity (NYSE:DOCS) Price Target to $28.00

Why Is Doximity Stock (DOCS) Falling Today, 5/14/26?